The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design.
This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.
Female sex
Age between 50 and 80 years
Willingness to participate in the study and signing of the informed consent
Clinical condition of post-menopause
Previous hysterectomy
Hormone replacement therapy
Immunosuppressive therapy